ANIK

Anika Therapeutics Inc. Common Stock

ANIK
Closed
$15.60
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Country

US

CEO

Mr. Stephen Griffin

IPO date

1985

Employees

235

ISIN

US0352551081

Website

anika.com

Key stats

Open

$16.12

Volume

53.53K

Market cap

$214.09M

Prev. close

$16.09

Impl / hst vl

-

Open interest

$0.00

$14.93

Day’s Range

$16.12

$9.01

52W Range

$16.49

Valuation

50
Valuation score
Fairly Valued
P/E
-
P/S
1.83
P/B
1.59
Current ratio
4.46
Debt / Equity
-0.31
ROE
-7.74%
Gross margin
64.15%
Income growth
-1,831.51%
FCF growth
-257.36

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$17.85
The top 4 analysts forecasts that 12-month price may increase by 14.42%, with a low of $17.17 and a high of $18.90
$17.17
Low
$17.85
Avg
$18.90
High
Current price

Earnings

Q1 ‘26 revenue
$29.61M
Q1 ‘26 net income
-$5.06M
Revenue
Net income
Previous EPS
$0.27
Estimate EPS
-$0.08
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply